Evolus Q3 revenue $61.1M (+22% YoY); narrows FY2024 guidance to $260-266M

Evolus, Inc.

2024-Q3 EPS reported -$0.71 revenue$187,327,000

Q3 net revenue $61.1M, up 22% from $50.0M in Q3 2023; year-to-date growth 33%.
Full-year 2024 revenue guidance narrowed to $260-266M (29-32% YoY growth).
Received EU approval for Estyme HA gels; U.S. PMA for Evolysse under FDA review, launch expected by Sep 2025.
Evolus Rewards loyalty program exceeded 1M enrolled consumers and 2M total redemptions.
Reaffirms positive non-GAAP operating income target for Q4 2024 and full year 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.